297 related articles for article (PubMed ID: 17764690)
1. Conformational dynamics of the molecular chaperone Hsp90 in complexes with a co-chaperone and anticancer drugs.
Phillips JJ; Yao ZP; Zhang W; McLaughlin S; Laue ED; Robinson CV; Jackson SE
J Mol Biol; 2007 Oct; 372(5):1189-203. PubMed ID: 17764690
[TBL] [Abstract][Full Text] [Related]
2. Blocking the chaperone kinome pathway: mechanistic insights into a novel dual inhibition approach for supra-additive suppression of malignant tumors.
Grover A; Shandilya A; Agrawal V; Pratik P; Bhasme D; Bisaria VS; Sundar D
Biochem Biophys Res Commun; 2011 Jan; 404(1):498-503. PubMed ID: 21144839
[TBL] [Abstract][Full Text] [Related]
3. Cdc37 (cell division cycle 37) restricts Hsp90 (heat shock protein 90) motility by interaction with N-terminal and middle domain binding sites.
Eckl JM; Rutz DA; Haslbeck V; Zierer BK; Reinstein J; Richter K
J Biol Chem; 2013 May; 288(22):16032-42. PubMed ID: 23569206
[TBL] [Abstract][Full Text] [Related]
4. Atomistic simulations and network-based modeling of the Hsp90-Cdc37 chaperone binding with Cdk4 client protein: A mechanism of chaperoning kinase clients by exploiting weak spots of intrinsically dynamic kinase domains.
Czemeres J; Buse K; Verkhivker GM
PLoS One; 2017; 12(12):e0190267. PubMed ID: 29267381
[TBL] [Abstract][Full Text] [Related]
5. Biochemical and structural studies of the interaction of Cdc37 with Hsp90.
Zhang W; Hirshberg M; McLaughlin SH; Lazar GA; Grossmann JG; Nielsen PR; Sobott F; Robinson CV; Jackson SE; Laue ED
J Mol Biol; 2004 Jul; 340(4):891-907. PubMed ID: 15223329
[TBL] [Abstract][Full Text] [Related]
6. Dual inhibition of chaperoning process by taxifolin: molecular dynamics simulation study.
Verma S; Singh A; Mishra A
J Mol Graph Model; 2012 Jul; 37():27-38. PubMed ID: 22609743
[TBL] [Abstract][Full Text] [Related]
7. Hsp90/Cdc37 chaperone/co-chaperone complex, a novel junction anticancer target elucidated by the mode of action of herbal drug Withaferin A.
Grover A; Shandilya A; Agrawal V; Pratik P; Bhasme D; Bisaria VS; Sundar D
BMC Bioinformatics; 2011 Feb; 12 Suppl 1(Suppl 1):S30. PubMed ID: 21342561
[TBL] [Abstract][Full Text] [Related]
8. Domain-mediated dimerization of the Hsp90 cochaperones Harc and Cdc37.
Roiniotis J; Masendycz P; Ho S; Scholz GM
Biochemistry; 2005 May; 44(17):6662-9. PubMed ID: 15850399
[TBL] [Abstract][Full Text] [Related]
9. Molecular chaperone complexes with antagonizing activities regulate stability and activity of the tumor suppressor LKB1.
Gaude H; Aznar N; Delay A; Bres A; Buchet-Poyau K; Caillat C; Vigouroux A; Rogon C; Woods A; Vanacker JM; Höhfeld J; Perret C; Meyer P; Billaud M; Forcet C
Oncogene; 2012 Mar; 31(12):1582-91. PubMed ID: 21860411
[TBL] [Abstract][Full Text] [Related]
10. Functional Role and Hierarchy of the Intermolecular Interactions in Binding of Protein Kinase Clients to the Hsp90-Cdc37 Chaperone: Structure-Based Network Modeling of Allosteric Regulation.
Stetz G; Verkhivker GM
J Chem Inf Model; 2018 Feb; 58(2):405-421. PubMed ID: 29432007
[TBL] [Abstract][Full Text] [Related]
11. Hsp90·Cdc37 Complexes with Protein Kinases Form Cooperatively with Multiple Distinct Interaction Sites.
Eckl JM; Scherr MJ; Freiburger L; Daake MA; Sattler M; Richter K
J Biol Chem; 2015 Dec; 290(52):30843-54. PubMed ID: 26511315
[TBL] [Abstract][Full Text] [Related]
12. Targeting Hsp90-Cdc37: A Promising Therapeutic Strategy by Inhibiting Hsp90 Chaperone Function.
Wang L; Li L; Gu K; Xu XL; Sun Y; You QD
Curr Drug Targets; 2017; 18(13):1572-1585. PubMed ID: 27231111
[TBL] [Abstract][Full Text] [Related]
13. In Vivo Conformational Dynamics of Hsp90 and Its Interactors.
Chavez JD; Schweppe DK; Eng JK; Bruce JE
Cell Chem Biol; 2016 Jun; 23(6):716-26. PubMed ID: 27341434
[TBL] [Abstract][Full Text] [Related]
14. Phosphorylation of serine 13 is required for the proper function of the Hsp90 co-chaperone, Cdc37.
Shao J; Prince T; Hartson SD; Matts RL
J Biol Chem; 2003 Oct; 278(40):38117-20. PubMed ID: 12930845
[TBL] [Abstract][Full Text] [Related]
15. Structural basis for recruitment of the ATPase activator Aha1 to the Hsp90 chaperone machinery.
Meyer P; Prodromou C; Liao C; Hu B; Roe SM; Vaughan CK; Vlasic I; Panaretou B; Piper PW; Pearl LH
EMBO J; 2004 Mar; 23(6):1402-10. PubMed ID: 15039704
[TBL] [Abstract][Full Text] [Related]
16. Large Rotation of the N-terminal Domain of Hsp90 Is Important for Interaction with Some but Not All Client Proteins.
Daturpalli S; Knieß RA; Lee CT; Mayer MP
J Mol Biol; 2017 May; 429(9):1406-1423. PubMed ID: 28363677
[TBL] [Abstract][Full Text] [Related]
17. Characterization of celastrol to inhibit hsp90 and cdc37 interaction.
Zhang T; Li Y; Yu Y; Zou P; Jiang Y; Sun D
J Biol Chem; 2009 Dec; 284(51):35381-9. PubMed ID: 19858214
[TBL] [Abstract][Full Text] [Related]
18. Exploring Mechanisms of Communication Switching in the Hsp90-Cdc37 Regulatory Complexes with Client Kinases through Allosteric Coupling of Phosphorylation Sites: Perturbation-Based Modeling and Hierarchical Community Analysis of Residue Interaction Networks.
Stetz G; Astl L; Verkhivker GM
J Chem Theory Comput; 2020 Jul; 16(7):4706-4725. PubMed ID: 32492340
[TBL] [Abstract][Full Text] [Related]
19. Targeting CDC37: an alternative, kinase-directed strategy for disruption of oncogenic chaperoning.
Smith JR; Workman P
Cell Cycle; 2009 Feb; 8(3):362-72. PubMed ID: 19177013
[TBL] [Abstract][Full Text] [Related]
20. Cdc37 maintains cellular viability in Schizosaccharomyces pombe independently of interactions with heat-shock protein 90.
Turnbull EL; Martin IV; Fantes PA
FEBS J; 2005 Aug; 272(16):4129-40. PubMed ID: 16098195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
